18,057 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by HealthInvest Partners AB

HealthInvest Partners AB acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 18,057 shares of the medical device company’s stock, valued at approximately $2,241,000. DexCom makes up about 1.8% of HealthInvest Partners AB’s holdings, making the stock its 21st biggest position.

A number of other hedge funds and other institutional investors also recently modified their holdings of DXCM. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DexCom by 31.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after acquiring an additional 65,516 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of DexCom by 3,596.7% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after purchasing an additional 1,079 shares during the period. West Family Investments Inc. purchased a new position in shares of DexCom in the 1st quarter worth about $209,000. Ergoteles LLC grew its position in DexCom by 60.6% during the first quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock valued at $860,000 after buying an additional 634 shares during the period. Finally, Mackenzie Financial Corp increased its holdings in DexCom by 26.4% during the first quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock worth $15,100,000 after buying an additional 6,160 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock traded up $1.96 during trading on Tuesday, hitting $136.52. The company had a trading volume of 3,036,341 shares, compared to its average volume of 2,992,702. The stock’s 50-day moving average is $128.82 and its two-hundred day moving average is $115.85. The stock has a market capitalization of $52.63 billion, a price-to-earnings ratio of 104.63, a price-to-earnings-growth ratio of 2.34 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the firm earned $0.34 EPS. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. As a group, analysts predict that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Insiders have sold 187,385 shares of company stock worth $25,256,617 over the last 90 days. Corporate insiders own 0.41% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DXCM. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Piper Sandler increased their target price on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Finally, Raymond James lifted their price target on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.